Last reviewed · How we verify
Treatment with oral sucrosomial iron
Treatment with oral sucrosomial iron is a Iron supplement (oral formulation) Small molecule drug developed by University of Rochester. It is currently FDA-approved for Iron deficiency anemia.
Sucrosomial iron delivers iron in a lipid-based carrier that enhances intestinal absorption and bioavailability while reducing gastrointestinal irritation.
Sucrosomial iron delivers iron in a lipid-based carrier that enhances intestinal absorption and bioavailability while reducing gastrointestinal irritation. Used for Iron deficiency anemia.
At a glance
| Generic name | Treatment with oral sucrosomial iron |
|---|---|
| Sponsor | University of Rochester |
| Drug class | Iron supplement (oral formulation) |
| Target | Iron (Fe3+) absorption pathway |
| Modality | Small molecule |
| Therapeutic area | Hematology / Nutritional deficiency |
| Phase | FDA-approved |
Mechanism of action
Sucrosomial iron encapsulates ferric iron within a proprietary sucrose-based lipid matrix that protects the iron from gastric acid and facilitates absorption in the small intestine. This formulation technology improves iron bioavailability compared to conventional iron salts while minimizing direct contact between iron and the intestinal mucosa, thereby reducing common gastrointestinal adverse effects associated with oral iron supplementation.
Approved indications
- Iron deficiency anemia
Common side effects
- Gastrointestinal disturbance (nausea, constipation, abdominal discomfort)
- Dark stools
- Headache
Key clinical trials
- Sucrosomial Vs Intravenous Iron for Preoperative Anemia (PHASE4)
- Effects of Iron Therapy in Heart Failure With Preserved Ejection Fraction and Iron Deficiency (PREFER-HF) (PHASE3)
- Sucrosomial Iron vs. Oral Iron Sulfate for the Treatment of Iron Deficiency Anemia in Patients With Ulcerative Colitis (PHASE3)
- Beneficial Effects of Vitamin D Combined With Oral Iron Supplementation in Patients With Chronic Heart Failure and Iron Deficiency (PHASE4)
- Sucrosomial Iron in Patients With Celiac Disease and IDA (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Treatment with oral sucrosomial iron CI brief — competitive landscape report
- Treatment with oral sucrosomial iron updates RSS · CI watch RSS
- University of Rochester portfolio CI
Frequently asked questions about Treatment with oral sucrosomial iron
What is Treatment with oral sucrosomial iron?
How does Treatment with oral sucrosomial iron work?
What is Treatment with oral sucrosomial iron used for?
Who makes Treatment with oral sucrosomial iron?
What drug class is Treatment with oral sucrosomial iron in?
What development phase is Treatment with oral sucrosomial iron in?
What are the side effects of Treatment with oral sucrosomial iron?
What does Treatment with oral sucrosomial iron target?
Related
- Drug class: All Iron supplement (oral formulation) drugs
- Target: All drugs targeting Iron (Fe3+) absorption pathway
- Manufacturer: University of Rochester — full pipeline
- Therapeutic area: All drugs in Hematology / Nutritional deficiency
- Indication: Drugs for Iron deficiency anemia
- Compare: Treatment with oral sucrosomial iron vs similar drugs
- Pricing: Treatment with oral sucrosomial iron cost, discount & access